Emergent BioSolutions: all 51 studies
Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsEnrolling by invitationNCT02051062Phase 4
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEnrolling by invitationNCT01374984
- A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsCompletedNCT05142306Phase 1Results posted
- A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsCompletedNCT04661839Phase 1Results posted
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 2Results posted
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 3Results posted
- Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)CompletedNCT03624946Phase 1Results posted
- Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ACompletedNCT03315104Phase 2Results posted
- Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy SubjectsTerminatedNCT02696291Phase 1Results posted
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIVCompletedNCT02443623Phase 4Results posted
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 4Results posted
- Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy SubjectsCompletedNCT02061358Phase 1Results posted
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 2Results posted
- Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 2Results posted
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 3Results posted
- Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)TerminatedNCT01311674Phase 3Results posted
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 1Results posted
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIVCompletedNCT01158157Phase 3Results posted
- CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaTerminatedNCT00893516Phase 2Results posted
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/2Results posted
- Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy AdultsCompletedNCT00679172Phase 2Results posted
- Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox VaccinationCompletedNCT00053495Phase 2Results posted
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 2Results posted
- Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsCompletedNCT05935917Phase 1
- Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsCompletedNCT05377255Phase 1
- Study of SIAN Nasal Spray in Healthy AdultsCompletedNCT05194358Phase 1
- Universal Influenza A Vaccine in Healthy AdultsCompletedNCT05155319Phase 1
- A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047TerminatedNCT03160339Phase 1
- Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsTerminatedNCT02771730Phase 1
- BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum AntitoxinCompletedNCT02055183
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
- A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 1
- BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT01653392
- Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelCompletedNCT01540929
- ACAM2000® Myopericarditis RegistryCompletedNCT01395082
- Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 1
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1CompletedNCT01006798Phase 1
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT00928577
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT00927719
- HuMax-CD4 in Non-Cutaneous T-Cell LymphomaCompletedNCT00877656Phase 2/3
- Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant PatientsCompletedNCT00722332Phase 4
- Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleCompletedNCT00636519Phase 1
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 1
- Safety Study of 7 Botulinum Antitoxin Serotypes Derived From HorsesCompletedNCT00360737Phase 1
- Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella InfectionApproved for marketingNCT00338442
- Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary SyndromeTerminatedNCT00127881Phase 3